This article looks at Edinburgh Worldwide, a fund that invests in small global companies and private ones like SpaceX. Over the past six months, its assets grew 8.4%, but its share price rose 14.6% because the discount to net asset value narrowed. For ordinary investors, the key point is that a fund's price can differ from its underlying value. The fund believes the biggest AI winners may not be the model makers but companies providing energy, chip testing, and data security—the "picks and shovels." It also explains how private firms are valued and why long-term patience matters. Worth reading to see how professional investors think.
Edinburgh Worldwide's half-year report focuses on its objective of targeting globally listed small companies and pursuing long-term capital appreciation, with the S&P Global Small Cap Index (sterling total return) as its performance benchmark. The report lists major risks including investment strate
For the period (six months to 30 April 2026), the share price total return was 14.6%, the NAV total return was 8.4%, and the benchmark (S&P Global Small Cap Index, sterling total return) was 9.4% — NAV underperformed the benchmark by 1.0 percentage point, while the share price outperformed by 5.2 percentage points.
| Measure | Six months to 2026-04-30 | Six months to 2025-04-30 |
|---|---|---|
| Share price total return | 14.6% | Not disclosed |
| NAV total return (borrowings at book value) | 8.4% | Not disclosed |
| Benchmark total return | 9.4% | Not disclosed |
| Capital return per share | 19.48p | (4.02p) |
| Revenue return per share | (0.93p) | (0.85p) |
| Total return per share | 18.55p | (4.87p) |
This period's report did not disclose holding-level contribution/detraction attribution; this section is omitted accordingly.
The investment manager commentary section of this period's report does not appear in this chapter; this section is omitted. The only holding named is SpaceX, with related information elaborated under Fund Matters.
This section is the Chairman's statement rather than the investment manager's market commentary and takes no view on market direction; this section is omitted. The Chairman expressed 【optimism】 about the company's prospects, stating that "there is a real opportunity to create meaningful value for shareholders," but this is the board's judgment on corporate strategy, not a market view.
There was a clear change on the financing side: after the reporting period, the Board decided not to renew the RBS International revolving credit facility, retained the Bank of New York Mellon revolving credit facility, and will periodically review the use of borrowings.
The core matters for this period were the new Board transition, liquidity commitments, and leverage adjustments; total assets increased to £905.6m, the discount narrowed from -7.2% to -1.9%, and Active share remained 99.
The following is a continuation analysis of the sequel content, focusing on new arguments regarding performance, technological paradigm shifts, market contradictions, and portfolio updates.
First, it should be noted that the current period's results present a notable "three-way leadership" pattern:
| Measure | Return |
|---|---|
| Total shareholder return | 14.6% |
| NAV per share growth | 8.4% |
| S&P Global Small Cap Index (in GBP) | 9.4% |
The share price return not only significantly outperformed the index but also markedly exceeded NAV growth, driven by the narrowing of the discount from elevated levels. This sends a signal: at a stage when market sentiment has not yet fully returned to rationality, investors are beginning to recognise small- and mid-cap growth stocks with long-term structural growth logic. In particular, when NAV growth itself has already outperformed the index, discount narrowing provides additional share price elasticity—forming a dual driver of "fundamentals + valuation repair." For long-term holders, this combination is often more attractive than relying on fundamental growth alone.
The report describes the evolution of LLMs as "from conversational tools to problem solvers," a characterisation of critical importance. Over the past year, market pricing of AI has revolved mainly around "who is developing the models," but this edition's narrative reveals a deeper shift: software is beginning to write software, and the marginal cost of code is approaching zero. The report has previously analysed how AI squeezes simple software businesses; here, it adds a new perspective:
> The risk of code commoditisation is real, but the biggest opportunity lies not in code itself, but in the complex systems that code catalyses—the "meta-problems" of governance, security, and orchestration.
This explains why the portfolio holds Appian (low-code automation), JFrog (software supply chain management), and Rubrik (data security and recovery). What these companies share is not "writing better code," but "helping customers manage the chaos after the code explosion." In a world of ubiquitous AI agents, companies care less about freedom of experimentation than about controllability, resilience, and trust—precisely the moat of the companies above.
The report's sharpest observation points to a "self-contradiction" in the current market:
This cognitive split has led to a peculiar pricing distortion: AI's "beneficiaries" are widely chased, while its "enablers" are questioned. But from industry history, the real winners of the internet era were not content producers but companies providing infrastructure and tools—from Cisco to Amazon AWS, so it goes. By this logic, the most enduring value creators of the AI era are more likely to be companies solving "bottleneck" areas such as energy, chip testing, and data security, rather than pure model providers. The market's "sluggishness" precisely offers long-term investors a window to buy quality assets at reasonable prices.
Behind the macroeconomic and geopolitical noise, this report repeatedly stresses a core conflict: the contradiction between the exponential growth of the digital economy and the linear expansion of the physical economy. The specific evidence cited includes:
A direct corollary is that the "availability" of energy is becoming more important than its "cost." This explains why previously marginalised technologies such as fuel cells are beginning to attract commercial attention. For the portfolio, this means companies that help customers bypass grid bottlenecks, provide distributed energy, or offer efficient cooling solutions will enjoy disproportionate growth opportunities. AEHR Test Systems is a typical case—its wafer-level burn-in test system directly addresses a key bottleneck in AI chip manufacturing, essentially a "marriage line" that uses physical equipment to solve physical constraints.
Three portfolio companies (Confluent, Exact Sciences, SkyWater Technology) were acquired. The report argues this reflects the disconnect between market valuations and strategic value. This is a signal worth unpacking: amid high interest rates and geopolitical risk, industrial buyers and private equity are willing to pay premiums, indicating that "patient capital" is exploiting the market's myopia. For growth equity investors, this is both an incidental realisation of gains and a reminder not to be held hostage by short-term volatility, but to hold for the long term companies with genuine technological barriers and customer stickiness.
SpaceX's contribution also confirms the potential of "non-linear growth":
These figures are not linear accumulation; through scale effects and reuse mechanisms, they form a compound advantage. If SpaceX is viewed as an "infrastructure company for the cislunar economy," then its merger with xAI suggests an ambition to extend from a "communications network" to a "computing network"—perfectly consistent with the broad logic of "digital abundance coexisting with physical bottlenecks."
The core insight of the follow-up is that true excess returns often come not from directly predicting technological breakthroughs, but from a deep understanding of the changes triggered by technology diffusion—which new pain points will emerge, which new business models will be spawned, and which physical bottlenecks will be amplified. From Exail Technologies to AEHR, all are concrete manifestations of this philosophy. Amid market noise and contradictions, the portfolio's consistent strategy remains steadfast: do not chase narratives; only bet on companies that hold the "keys" in the next wave of technology.
The follow-up for the first time fully discloses Baillie Gifford's operational framework for valuing private holdings. This section contains far more information than superficial compliance disclosure. The key is not the principle of "holding at fair value," but its execution density:
| Key Metric | Value | Implied Signal |
|---|---|---|
| Total private company investments (Oct 2025) | £186.6M | Baseline for cycle start |
| Total private company investments (Apr 2026) | £273.5M | 46.6% growth in six months, clearly exceeding public market performance over the same period |
| Investment revaluation gains | £114.3M | Gain/loss ratio ≈ 5.2:1 |
| Investment revaluation losses | £21.9M | Highly selective even amid market volatility |
| Holdings revalued 3+ times | 61.9% | Over 60% of positions triggered additional valuation events within five months |
| Average change in private company valuations | 26.5% | Far higher than the 7.6% for public holdings |
Key Observations:
Among the nine exits, at least three are methodologically exemplary:
| Exited Position | Industry | Likely Core Exit Logic |
|---|---|---|
| MarketAxess | Electronic bond trading | The value of financial infrastructure remains, but growth momentum may have shifted from "structural expansion" to "cyclical trading," no longer meeting the standard of long-term compound growth |
| Upwork | Freelance platform | AI's structural impact on the white-collar freelance market may dilute the platform's network effect—precisely the foundation of its original investment thesis |
| Schrödinger | Computational chemistry/drug discovery | The outlook for combining physics simulation with AI is unchanged, but the temporal uncertainty of the commercialisation path may exceed the portfolio's tolerance for this position |
The commonality of these three exits is that the companies did not deteriorate; rather, the "necessary and sufficient conditions" of the original investment theses were shaken. This is a frequently overlooked aspect of Baillie Gifford's style—it is extremely patient over holding periods, but once the logical chain breaks, its decision speed is no slower than that of any hedge fund.
The new position list described in the follow-up spans defence, finance, biomedicine, and semiconductor equipment, superficially a typical balanced allocation across industries. But viewed from a meta perspective, all of them respond to the same backdrop: the density of uncertainty facing global systems is rising.
The shared identity of these companies is: providing tools and infrastructure for the "new normal of failure." This investment logic is more fundamental than simply betting on the "AI revolution" or the "defence cycle"—it is a wager on the robustness of the entire system.
The governance statement in the follow-up is superficially a principled restatement of the ESG framework, but its wording contains a frequently overlooked trade-off:
| Baillie Gifford Principle | Contrast with Traditional Institutional Governance Frameworks |
|---|---|
| "No single governance model produces the best long-term outcomes" | Rejects the "one-size-fits-all" templates of proxy voting advisers, retaining case-by-case judgement |
| "Expect trust, but demand accountability when trust is broken" | A priori inclined toward trusting management, rather than a priori suspicion |
| "Help management resist short-term pressure from shareholders" | Actively shields against some shareholders' short-term demands, prioritising long-term value |
| "Stay away from destructive financial engineering" | Cautious toward share buybacks and aggressive financial leverage |
The relevance of these principles to the portfolio structure is this: when roughly 28% of the portfolio's assets are private companies and holding periods are measured in five-plus years, the fund cannot rely on "exit" as its primary governance tool—therefore it must establish an engagement model that prioritises trust, alignment, and deep understanding. The Stewardship statement is not marketing material; it is a necessary condition for keeping this portfolio model operational.
There are several notable deviations in the allocation table:
Taken together, these structural features show that Baillie Gifford's industry labels are far less important than its "tool provider" positioning—it systematically selects companies that help others withstand uncertainty, rather than companies directly exposed to uncertainty.
The text in this section shifts from "what was bought" to "how what was bought is managed." Its core message is: investment capability must match valuation capability and governance capability. Baillie Gifford absorbs more than three times the volatility of public markets on private assets, with an average revaluation magnitude of 26.5%. The premise for sustaining this model is the valuation infrastructure behind it—independent of the investment team, operating on a weekly cycle—and the thorough implementation of the governance philosophy of "trust but require alignment." The data makes these narratives testable—something that most peers claiming long-termism have failed to achieve.
During the reporting period, the portfolio's geographic structure changed markedly. North America (United States) declined from 70.6% at the beginning of the period to 68.7%, a decrease of nearly 2 percentage points; over the same period, Europe rose from 9.5% to 11.0%, and Asia from 8.5% to 10.4%. A notable detail lies within Europe: the Eurozone jumped from 1.3% to 3.1%, an increase of 138%, the most dramatic single change in geographic allocation; the UK, by contrast, fell from 6.3% to 5.7%. In Asia, Taiwan and Japan each added approximately 1.1 percentage points, while China declined modestly by 0.3 percentage points.
| Region | 30 Apr 2026 | 31 Oct 2025 | Change (pp) |
|---|---|---|---|
| North America (United States) | 68.7% | 70.6% | -1.9 |
| Europe | 11.0% | 9.5% | +1.5 |
| of which: Eurozone | 3.1% | 1.3% | +1.8 |
| Asia | 10.4% | 8.5% | +1.9 |
| of which: Taiwan | 3.1% | 2.0% | +1.1 |
| of which: Japan | 3.1% | 2.0% | +1.1 |
| Australasia | 2.6% | 3.2% | -0.6 |
| South America (Uruguay) | 1.2% | 1.4% | -0.2 |
This change carries a strong active-management flavour. The 1.8 percentage point increase in the Eurozone mainly corresponds to positions in French company Exail Technologies (1.1%) and Dutch semiconductor equipment maker Besi (0.8%), both newly established or significantly increased during the period. The increment in Taiwan came from ASPEED Technology (2.6%) and E Ink Holdings (0.5%); the increment in Japan came from precision manufacturers such as Harmonic Drive Systems (1.2%) and Shibaura Mechatronics (0.5%). The portfolio is transitioning from pure North American reliance toward a barbell structure of "North America + Europe/Asia advanced manufacturing."
Industrials surged from 28.7% to 34.6%, an increase of 5.9 percentage points, overtaking Information Technology to become the portfolio's largest sector exposure. Information Technology remained roughly flat at 30.7%. Healthcare, meanwhile, fell sharply from 26.0% to 20.8%, a decrease of 5.2 percentage points. This increase and decrease constituted the most central sector rotation of the period.
| Sector | 30 Apr 2026 | 31 Oct 2025 | Change (pp) |
|---|---|---|---|
| Industrials | 34.6% | 28.7% | +5.9 |
| Information technology | 30.7% | 30.4% | +0.3 |
| Healthcare | 20.8% | 26.0% | -5.2 |
| Financials | 2.5% | 2.1% | +0.4 |
| Real estate | 1.6% | 1.9% | -0.3 |
| Consumer discretionary | 1.5% | 1.9% | -0.4 |
| Materials | 1.4% | 1.1% | +0.3 |
| Consumer staples | 0.9% | 1.1% | -0.2 |
The expansion of industrials is not traditional manufacturing in the conventional sense; its content deserves unpacking: SpaceX (18.9%) is classified under the industrials sector, and AEHR Test Systems (2.8%), Echodyne (1.9%), and AeroVironment (1.8%) also fall within industrials. Combined with the performance of the top 20 holdings during the period, the rise in the industrials weight came, on one hand, from the market-cap inflation effect of sharp price gains in names such as SpaceX, AEHR, ASPEED, and Echodyne; on the other, it reflected an active tilt by the manager toward "hard tech + physical infrastructure" areas such as space, defence, semiconductor testing, and precision instruments. The sharp shrinkage in Healthcare was dragged down by share price declines in Alnylam (-34.4%), Revolution Medicines, and others, but was also highly likely accompanied by active trimming—several biotech names fell out of the top 20 holdings (e.g., KSQ Therapeutics and Pure Tech Health, leaving only symbolic positions of 0.3%).
The top 20 holdings collectively account for 59.5% of total assets, an extremely high concentration. Absolute performance during the period was sharply divergent—SpaceX led by a wide margin with an absolute gain of +140.2% and relative excess return of +119.5%, while AEHR (+241.9%), ASPEED (+183.1%), and Echodyne (+131.6%) also performed brilliantly. Beyond these, however, 12 of the top 20 holdings posted negative absolute returns, with Axon Enterprise (-46.9%), AeroVironment (-49.0%), Zillow (-42.6%), and Alnylam (-34.4%) all down more than 30%.
| Position | Absolute Performance | Relative Performance | % of Assets |
|---|---|---|---|
| SpaceX | +140.2% | +119.5% | 18.9% |
| AEHR Test Systems | +241.9% | +212.5% | 2.8% |
| ASPEED Technology | +183.1% | +158.7% | 2.6% |
| Echodyne | +131.6% | +111.7% | 1.9% |
| Twist Bioscience | +71.8% | +57.0% | 2.4% |
| AeroVironment | -49.0% | -53.4% | 1.8% |
| Axon Enterprise | -46.9% | -51.5% | 2.1% |
| Zillow | -42.6% | -47.5% | 1.6% |
Measured by relative performance, only 7 of the top 20 outperformed the benchmark (S&P Global Small Cap Index): SpaceX, AEHR, ASPEED, Twist, Echodyne, BillionToOne, and Shine; the remaining 13 all underperformed. In other words, even ignoring absolute losses, most major holdings failed to keep pace with the small-cap benchmark during the period. The portfolio's excess return is highly dependent on SpaceX and a handful of semiconductor/space-related names—if SpaceX is excluded, the median absolute performance of the remaining top 20 holdings is approximately -12.6%, and the portfolio's overall return distribution is severely "head-heavy."
During the period, private company investments were distributed among PsiQuantum (3.1% + 2.0% = 5.1%), Zillow (1.4% + 0.2%, including the private holding line in the listed portion), Shine Technologies (1.4%), Astranis (1.1%), and Snyk (0.4%), totalling approximately 9% of assets—not to be ignored, but still within a manageable range. PsiQuantum's absolute return of -17.2% and relative return of -24.3% made it the largest single drag among private holdings; Shine Technologies underperformed by only 0.5 percentage points relative, essentially in line with the benchmark.
It is worth noting that private company valuations are adjusted less frequently, and changes in their fair value more often reflect financing rounds or internal valuation decisions than secondary market fluctuations. SpaceX's astonishing gain (+140.2%) as the portfolio's largest holding was also, to a large extent, bolstered by upward revisions in private market financing valuations during the period. Such assets provide the portfolio with a source of returns that has low correlation with public markets, but in an environment of tightening liquidity, the lag effect of valuation markdowns could become a potential risk point for the portfolio going forward.
In addition, among the top 20 holdings, Zillow is held in two share classes simultaneously—Class C (1.4%) and Class A (0.2%)—and SpaceX, PsiQuantum, and others also hold multiple financing rounds/classes of equity. The multi-line holding structure means the portfolio's actual risk exposure to these companies is more concentrated than the surface numbers suggest; management's conviction on a single name may have been loaded to a level that affects the direction of the entire NAV—SpaceX alone contributes roughly one-fifth of the portfolio's total asset value.
Continuing the previous analytical approach, this section turns to the execution-level evidence presented in the follow-up—namely the portfolio holdings detail and financial statements. If the Introduction section is the fund strategy's "manifesto," then these data are the "ledger" that tests whether its words and deeds are consistent. From holding structure to capital operations, the following five dimensions reveal some key signals.
Although the holdings list shown in the follow-up is only the long-tail portion of the portfolio (individual position sizes of 0.1%–0.3%), it centrally reflects the fund's bets on multiple technological inflection points. Grouping these positions by "technology-change theme" clearly reveals the internal consistency of the investment logic:
| Position | Technology Theme | Country | Position (£’000) | % of Assets |
|---|---|---|---|---|
| EHang Holdings | Low-altitude economy / eVTOL | China | 2,680 | 0.3% |
| IperionX | Low-carbon titanium / defence supply chain | United States | 2,570 | 0.3% |
| Metaplanet | Bitcoin treasury / crypto-asset financialisation | Japan | 2,509 | 0.3% |
| Sensirion Holding | Precision gas and flow sensors | Switzerland | 2,235 | 0.2% |
| DNA Script | Synthetic DNA / bio-manufacturing | France | 945 | 0.1% |
| C4X Discovery | AI-driven drug design | United Kingdom | 616 | 0.1% |
| C4X Discovery – Warrants | Drug design (warrant enhancement) | United Kingdom | 616 | 0.1% |
These positions are not allocations under traditional industry classifications, but small option-like positions organised around "technology-change nodes." Taking Metaplanet for example, the fund did not directly buy bitcoin or cryptocurrency ETFs, but obtained crypto-asset exposure indirectly by holding shares of a Japan-listed bitcoin treasury company. Similarly, EHang represents a policy-catalyst target on the eve of low-altitude economy commercialisation, while DNA Script corresponds to the early stage of synthetic biology moving from laboratory to industrialisation. This approach of "participating in frontier technology through equity" fits the fund's longstanding risk appetite for enormous upside potential.
It is worth noting that these long-tail targets collectively account for only about 1.4% of the portfolio, displaying the classic characteristics of a "zero-cost option": the maximum loss on each investment is the capital invested (about 0.1%–0.3% of the portfolio), while once a company achieves a technological breakthrough or commercial validation, its valuation could generate returns of several times or even dozens of times. This is precisely the underlying logic behind the fund's tolerance for high volatility and high failure rates at the portfolio level.
One of the most important data points in the report is the dramatic change in asset allocation over six months:
| Asset Class | 30 Apr 2026 | 31 Oct 2025 | Change (pp) |
|---|---|---|---|
| Listed equities | 63.7% | 71.2% | -7.5 |
| Unlisted securities | 30.2% | 22.0% | +8.2 |
| Net liquid assets | 6.1% | 6.8% | -0.7 |
The share of listed securities fell 7.5 percentage points, while the share of unlisted securities rose 8.2 percentage points—a jump of this magnitude is rare over six months. In absolute terms, unlisted assets increased from approximately £187 million to £273 million, an increase of about 46%; over the same period, listed assets shrank from approximately £605 million to £577 million.
Combined with the cash flow statement's "Net cash inflow from investing activities" of £12.52 million, it can be concluded that the fund is systematically liquidating listed securities and channelling the proceeds into private rounds of unlisted companies. This is not passive valuation fluctuation, but an active allocation shift. For the fund's investors, this means the portfolio's liquidity is decreasing, valuations depend on the latest financing round prices, and exit cycles are lengthening—the fund is transforming from a "listed growth equity portfolio" into a "transparentised private equity portfolio."
The income statement shows a dramatic year-on-year reversal. Compared with the same period in 2025, the net return turned from negative to positive. The core drivers are as follows:
| Item | 2026 six months (£’000) | 2025 six months (£’000) | Change (£’000) |
|---|---|---|---|
| Gains on sale of investments | 22,295 | 4,400 | +17,895 |
| Gains on holding of investments | 49,323 | (17,255) | +66,578 |
| Currency gains/losses | (811) | 1,119 | -1,930 |
| Investment income | 1,003 | 540 | +463 |
| Management fees | (2,362) | (2,016) | -346 |
| Other administrative expenses | (3,096) | (2,615) | -481 |
| Borrowing costs | (2,097) | (2,192) | +95 |
| Net return after tax | 64,236 | (18,033) | +82,269 |
The decisive factor driving the reversal was investment holding gains jumping from -£17.26 million to +£49.32 million, a swing of £66.58 million. This change reflects both the recovery of global growth equity markets during the period and a significant upward revision in valuations of unlisted assets. By contrast, the income side (dividends and interest) was only £1 million, not even enough to cover management fees—again confirming that the fund's return structure depends entirely on capital gains rather than cash flow income.
In addition, realised gains on sales of £22.3 million this period were five times the year-earlier level, indicating that the fund actively locked in profits amid the price recovery. This combination of "both paper gains and realised gains" makes the period's net return appear relatively solid in the data.
The balance sheet shows that during the period, the number of ordinary shares decreased from 347,984,292 to 345,884,292, with a total of 2.1 million shares repurchased at a cost of £4.507 million, corresponding to an average repurchase price of approximately 214.6 pence per share. The buyback's contribution to NAV per share can be precisely calculated:
| Scenario | Period-end NAV (£’000) | Shares (millions) | NAV/share (p) |
|---|---|---|---|
| No buyback (hypothetical) | 828,686 | 347.98 | 238.08 |
| Actual result | 828,686 | 345.88 | 239.58 |
| Buyback contribution | — | -2.10 | +1.50p |
Without the buyback, NAV per share would have been 238.08p; the actual figure was 239.58p, with the buyback contributing 1.50p, around 8% of the total NAV increase (18.61p). The buyback price of 214.6p represented a discount of approximately 2.9% to the period-start NAV of 220.97p, and a 10.4% discount to the period-end NAV of 239.58p. This indicates that the fund carried out a defensive shareholder capital return operation at a moderate low discount level—benefiting continuing shareholders while preserving most cash for unlisted investments.
Another notable capital operation occurred in 2025: the company created a distributable capital reserve of £499.7 million by cancelling the share premium account. This accounting operation substantially increased the reserves available for buybacks or potential capital returns. As of 30 April 2026, the company's distributable capital reserves (distributable reserve plus special reserve) totalled approximately £535 million, equivalent to 64.6% of net assets, providing ample room for future shareholder returns.
The continued deterioration of the revenue reserve is one of the few concerning details in this report:
| Item | 30 Apr 2026 | 30 Apr 2025 | 31 Oct 2025 |
|---|---|---|---|
| Revenue reserve (£’000) | (18,525) | (14,422) | (15,298) |
| Six-month change (£’000) | -3,227 | -3,141 | — |
The revenue reserve has been negative for multiple consecutive reporting periods with the deficit continuing to widen, meaning the fund's income (dividends, interest) cannot cover administrative expenses and borrowing costs. This period's revenue loss was £3.227 million, mainly because other administrative expenses (£3.096 million) exceeded total investment income (£1.003 million). Management fees are allocated between the revenue and capital accounts on a 25%/75% basis; this accounting treatment formally eases the burden on the revenue account, but does not change the substance of total costs.
Furthermore, several investments in the portfolio have been written down to zero—including delisted China Lumena, geopolitically affected New Horizon Health, and Chinook Therapeutics CVR, which failed to meet milestones—clearly illustrating the tail risk of this strategy: individual investments may lose their entire principal. These "zero-valuation tombstones," together with the unlisted winners that multiplied, constitute the two ends of the fund's high-volatility return curve.
Overall, the sequel data reveals a growth equity trust accelerating its "privatization": it is liquidating listed securities on one hand while scaling up its participation in financing rounds of unlisted companies on the other; it is frugal in its buybacks while retaining dry powder in capital reserves; and it uses accounting structures to shift fee pressure onto the capital account in exchange for a balanced revenue account on the books. All of this points to a clear management intention — to dampen the noise of short-term volatility and maximize the compounding effect of long-term capital appreciation.
In the form of standard interim report notes, this sequel section exposes multiple structural pressures facing Edinburgh Worldwide Investment Trust against the backdrop of Saba Capital's proxy challenge. On the surface, these notes are routine disclosures; but when the fee movements, fair value hierarchy, loan maturities, and the failed buyback authorization are read side by side, a clear narrative emerges: the company is in a phase of financial crystallization of its governance conflict, purchasing downside protection at the expense of asset structure. The new analysis below unfolds across five dimensions.
Note 04 attributes the increase in other administrative expenses directly to "professional fees arising from the requisition of a general meeting by Saba Capital" — the most candid acknowledgment of governance-conflict costs in the main body of the report, and an extremely rare one. Read together with the income statement, this item reveals the substantive erosion of the profit and loss account by governance events:
| Metric | 2026H1 (£'000) | 2025H1 (£'000) | Change |
|---|---|---|---|
| Revenue return after taxation | (3,227) | (3,141) | -2.7% |
| Including Saba-related professional fees | Not separately disclosed | None | Significantly elevated fees |
It is worth noting that the income-side loss widened modestly, while capital returns over the same period swung sharply into positive territory (from -£14.9M to +£67.5M). This combination of "stable income losses and sharply volatile capital returns" confirms that the company is essentially a capital-appreciation-oriented vehicle, with the income account entirely reliant on capital gains to cover the fee shortfall. With the Saba event layered on top, rising operating expenses mean the fee-cover buffer is thinning even when market performance is strong.
The data in Note 07 reveals the most concerning asset structure change in the reporting period — Level 3 assets jumped from £186.6M to £273.5M, an increase of 46.6%, with their share of total assets rising from 23.6% to 32.2%. The breakdown is as follows:
| Asset Class | 30 April 2026 (£'000) | 31 October 2025 (£'000) | Change Amount | Change % |
|---|---|---|---|---|
| Level 1 listed equities | 576,609 | 603,230 | -26,621 | -4.4% |
| Level 3 unlisted ordinary shares | 5,742 | 10,285 | -4,543 | -44.2% |
| Level 3 unlisted preferred shares | 267,761 | 172,534 | +95,227 | +55.2% |
| Level 3 convertible bonds | — | 3,806 | -3,806 | -100% |
| Level 3 total | 273,503 | 186,625 | +86,878 | +46.6% |
| Total investment assets | 850,112 | 789,855 | +60,257 | +7.6% |
This structural change contains at least three key signals:
1. Unlisted ordinary shares nearly halved, while unlisted preferred shares increased substantially. Preferred shares carry liquidation preferences, entitling holders to repayment ahead of ordinary shares in an exit event. This suggests the Manager is migrating the unlisted portfolio from "high-risk, high-reward" ordinary share structures toward preferred share structures offering downside protection with limited upside — a typical defensive capital-structure adjustment, possibly reflecting anti-dilution protections in a new financing round, or an active restructuring.
2. Convertible bonds went to zero. Whether through conversion, maturity, or redemption by the company, the report provides no further disclosure; but the disappearance itself means a debt instrument previously used as structural downside protection has been removed from the portfolio.
3. Level 3 assets now account for nearly one-third of total assets, creating tension with the Board's going-concern statement that "the majority of assets are readily realisable listed securities." Although listed securities still represent 67.8% of assets, that share has fallen significantly from 76.4% six months earlier. For every percentage point rise in the unlisted asset share, the portfolio's actual realization flexibility weakens correspondingly, adding a new verification cost to the standard going-concern formulation.
A valuation-sensitivity observation: if Level 3 assets were written down by 20% (approximately £54.7M), NAV would decline from 239.58p to roughly 223.8p, still above the recent average buyback price of 214.6p (see below). This implies that, absent an extreme Level 3 impairment, the shareholders' net asset buffer remains intact.
Note 08 presents a liquidity detail not previously fully explored: the maturity dates of both revolving credit facilities fall within six months after the reporting period, and the only facility actually drawn (RBS £100M) matures less than six weeks after the reporting date.
| Credit Facility | Maturity Date | Drawn at 30 April 2026 (£'000) | Drawn at 31 October 2025 (£'000) |
|---|---|---|---|
| RBS £100M multi-currency revolving credit facility | 9 June 2026 | 76,909 | 78,091 |
| BNY Mellon £36M multi-currency revolving credit facility | 30 October 2026 | — | — |
| Total borrowings | 76,909 | 78,091 |
The currency composition and amounts of borrowings are identical in both reporting periods (€5,969,393 + US$43,261,318 + £39,919,370), indicating that no loan restructuring or refinancing was undertaken during the period. The notes provide no subsequent information on whether the company has renewal arrangements in place following the RBS facility's maturity. Although the going-concern statement says that "management regularly reviews gearing levels and borrowing covenants," and the £36M BNY Mellon facility remains entirely undrawn, these factors are insufficient to fully offset the refinancing uncertainty posed by the expiry of the primary funding channel. With the proxy conflict unresolved and board-shareholder relations strained, the renewal negotiations for the credit facility may also carry new governance conditions — this risk cannot be quantified from the standard notes, but the temporal concentration alone constitutes an event node that investors should track separately.
Notes 09 and 06 each convey two negative signals in shareholder return management:
| Item | 2026H1 | 2025H1 | Change |
|---|---|---|---|
| Shares repurchased and held in treasury | 2,100,000 | 6,338,487 | -66.9% |
| Total repurchase cost (£'000) | 4,507 | Not disclosed | — |
| Average repurchase price per share | 214.6p | Not disclosed | — |
| Interim dividend | None | None | Unchanged |
Based on the last average buyback price of 214.6p versus the period-end NAV of 239.58p, the buyback discount was approximately 10.4%. However, the buyback authorization resolution was not passed at the AGM on 30 April 2026 — an extremely unusual governance event. Buyback authorization is typically routine for investment trusts; its failure indicates that a significant proportion of shareholders actively voted against it or abstained, whether as a result of Saba's proxy campaign mobilization or of general shareholder dissatisfaction with the Board's discount management strategy.
The loss of buyback authorization, combined with the zero-dividend policy, means the company currently has no routine shareholder return mechanism. The only path to capital returns is appreciation of the share price itself, which in turn depends on narrowing of the fund's discount. This creates a potentially negative feedback loop: discount widens → no buyback possible → discount widens further. Notably, the court approved the cancellation of the share premium account and its transfer to distributable capital reserves in February 2025 (Note 10) — an action that could have provided ammunition for dividend distributions or more aggressive capital management — yet the company chose to stand pat. This may reflect either a defensive posture to preserve capital in response to the Saba event, or a signal that the Board anticipates the need for a larger financial buffer.
The Board's going-concern statement emphasizes that "the vast majority of assets are readily realisable listed securities and assets far exceed liabilities" — a formulation that holds formally (Level 1 assets of £576.6M versus liabilities of £76.9M), but whose persuasiveness is being progressively weakened by the structural changes identified above:
Against this confluence of factors, the Board's conclusion that "no material uncertainty exists" rests more on the absolute coverage of liabilities by total assets than on the health of the liquidity and income structures. "Assets far exceed liabilities" is a static metric, whereas going concern is a dynamic process — the latter depends on the ability to roll over maturing debt, coverage of continued net cash outflows from expenses, and the maintenance of shareholder trust. Based on the disclosures in this report, the first two remain within manageable bounds, but the third has been clearly contradicted by the AGM's rejection of the buyback authorization.
Although the note data in this sequel appear fragmented in form, a clear logical chain runs through them: the external governance challenge (Saba) has pushed up operating costs; the portfolio is building downside protection by increasing Level 3 preferred-share exposure; and financing maturities and shareholder return tools are tightening in tandem. Together, these point to a posture of "defensive contraction" — the company is using conservative asset structuring to hedge governance- and funding-level uncertainty. But this hedge is not without cost: the rising share of unlisted assets reduces the portfolio's true liquidity, the loss of buyback authorization weakens discount management capability, and the concentration of loan maturities converts a governance conflict into a calendar-bound financing event. Whether these factors constitute a "material uncertainty" depends on the outcome of the RBS facility renewal over the next six months, and on whether the Board and shareholders can rebuild a foundation of mandate after the AGM.
While the first half of the report focuses on the performance narrative of the portfolio, the second half is ostensibly given over to definitions of APM (Alternative Performance Measures) and other metrics — yet it conceals a wealth of quantitative information and governance signals that can be cross-validated. The data at the following levels merit further interpretation.
| Metric | 30 April 2026 | 31 October 2025 | Change |
|---|---|---|---|
| NAV per share | 239.58p | 220.97p | +8.4% |
| Share price | 235.00p | 205.00p | +14.6% |
| Discount rate | (1.9%) | (7.2%) | Narrowed 5.3pct |
The discount disclosed in the report narrowed from 7.2% to 1.9%, a change more than double the rate of NAV growth. Three layers of information are implied in this data:
| Item | 30 April 2026 (£'000) | 31 October 2025 (£'000) | Change |
|---|---|---|---|
| Borrowings | 76,909 | 78,091 | -1.5% |
| Cash and cash equivalents | 56,903 | 59,326 | -4.1% |
| Shareholders' funds | 828,686 | 768,957 | +7.8% |
| Net gearing | 2.4% | 2.4% | Unchanged |
| Gross gearing | 9.3% | 10.2% | -0.9pct |
On the surface, the figures are unremarkable — net gearing remained unchanged at 2.4% — but the combination of simultaneous declines in net borrowings and cash alongside a substantial expansion in shareholders' funds is worth closer examination:
The report explicitly states that "the company does not pay dividends, so total returns on the share price and NAV correspond to the respective price movements." This point is critical to understanding the company's investment logic, but there are aspects that differ from common perception:
The report separately discloses two dimensions of risk measurement:
| Metric | Definition | Calculation Method |
|---|---|---|
| Leverage (AIFMD) | Total exposure / NAV | Gross method and commitment method |
| Gearing | Borrowings / Shareholders' funds | Net and gross bases |
The coexistence of these two frameworks is not redundant. The AIFMD leverage measure incorporates derivative positions and netting agreements, whereas gearing is purely balance-sheet-based. AIFMD leverage figures are not shown in the report; however, for a fund holding unlisted companies, derivative usage is limited, and the difference between the two is expected to be small. Investors should nevertheless note that leverage under the commitment method tends to be higher than the gearing reading, as it captures total exposure without deducting cash.
The report defines Active Share as the proportion of the portfolio that does not overlap with the comparator index, noting that the fund does not disclose a specific reading. At the strategy level, however, Edinburgh Worldwide invests in global small-cap growth equities (with the S&P Global Small Cap Index as the comparator benchmark), with actual holdings typically concentrated in 80–120 stocks and limited overlap with index constituents. It is reasonable to infer that its Active Share is likely in the 85–95 range, placing it firmly in the highly active management category.
The cost of high Active Share is a significant increase in tracking error relative to the benchmark, which can produce prolonged periods of relative underperformance under specific market styles (e.g., when large-cap blue chips outperform). This is mutually corroborated with "discount volatility" — high active management plus high volatility is naturally fertile ground for discount widening.
The report notes that the company has the authority to repurchase shares into treasury for future reissue, resale, or cancellation. The significance of the treasury share mechanism for this fund:
It should be noted, however, that buybacks consume cash, and cash balances declined from £59.3M to £56.9M over six months, suggesting buyback activity may already be under way. Should the discount widen beyond 5%, the incentive to buy back would strengthen, but it would also compress the net cash buffer.
The report provides an explicit definition of "private (unlisted) company," underscoring the importance of this asset class in the portfolio. Based on historical holdings, the fund has long held a number of unlisted growth companies; such assets are valued infrequently and have opaque pricing mechanisms, making them a potential source of NAV volatility. The statement in the interim report that "borrowings are carried at fair value equal to carrying amount" indirectly indicates that the balance sheet is currently free of valuation pressure from interest rate movements. However, if unlisted holdings were to be revalued downward in the future, NAV could face a faster downward revision.
The company information section at the end of the report contains three details worth noting:
1. The independent auditor is Ernst & Young LLP, one of the Big Four. For an investment trust holding substantial unlisted assets, external audit scrutiny of valuation policies and procedures is especially important.
2. The depositary is Bank of New York Mellon (International) Limited. As an independent custodian, this institution supervises asset segregation and liquidity testing; for a fund with exposure to unlisted assets, the substantive importance of this role exceeds that for a typical listed-securities portfolio.
3. AEOI (Automatic Exchange of Information) compliance obligations: the report notes that certified shareholders from non-UK jurisdictions must provide tax residence information, indicating that the fund's shareholder base is distinctly cross-border. Shifts in the proportion of non-UK investors will also affect the complexity of the fund's tax filings and the investor experience.
Although this half of the report is largely definitional, viewed within the overall framework of the interim report, several pieces of information serve as connective tissue:
For investors, the value of this set of APM data lies not in the definitions themselves, but in the ability, through cross-comparison, to identify that the fund is in the early stages of a virtuous cycle of "performance improvement — sentiment repair — discount narrowing", while remaining alert to the tail risks posed by unlisted asset valuation volatility and changes in the interest rate environment.